Angiodynamics reports fiscal year 2025 first quarter financial results

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended august 31, 2024. fiscal year 2025 first quarter highlights   quarter ended august 31, 2024 pro forma* yoy growth net sales $67.5 million.
ANGO Ratings Summary
ANGO Quant Ranking